RecombiMAb anti-mouse CD16/CD32
Fc receptor blocking, flow cytometry*
Fc receptor blocking, immunofluorescence*
*Reported for the original rat IgG2b 2.4G2 antibody
(switched from rat IgG2b)
Product Description
Specifications
| Isotype | Mouse IgG2a, κ |
|---|---|
| Recommended Isotype Control(s) | RecombiMAb mouse IgG2a isotype control, anti-hen egg lysozyme |
| Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
| Conjugation | This product is unconjugated. Conjugation is available via our Antibody Conjugation Services. |
| Immunogen | BALB/c mouse macrophage cell line J774 |
| Reported Applications |
in vivo Fc receptor blocking* Fc receptor blocking, flow cytometry* Fc receptor blocking, immunofluorescence* *Reported for the original rat IgG2b 2.4G2 antibody |
| Formulation |
PBS, pH 7.0 Contains no stabilizers or preservatives |
| Endotoxin |
≤0.5EU/mg (≤0.0005EU/μg) Determined by LAL assay |
| Aggregation |
<5% Determined by SEC |
| Purity |
≥95% Determined by SDS-PAGE |
| Sterility | 0.2 µm filtration |
| Production | Purified from HEK293 cell supernatant in an animal-free facility |
| Purification | Protein G |
| Molecular Weight | 150 kDa |
| Murine Pathogen Tests |
Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
| Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
| Need a Custom Formulation? | See All Antibody Customization Options |
Product Citations
-
Myeloid reprogramming generates myeloid-derived activating cells to potentiate radiotherapy and suppress metastasis.
In Cancer Cell on 12 October 2026 by Ji, F., Zheng, L., et al.
PubMed
Radiation induces immunosuppressive myeloid cells that drive therapeutic resistance and metastasis. We identify TET2 as a radiation-induced regulator of myeloid-derived suppressor cells whose expression correlates with poor outcomes in advanced lung cancer patients receiving radio-immunotherapy. Following radiotherapy, myeloid-specific Tet2 deletion suppresses tumor progression and redirects monocyte differentiation toward antigen-presenting myeloid-derived activating cells (MDACs), which augment antitumor T cell responses; spatiotemporal mapping shows that this fate program initiates rapidly in the bone marrow. Mechanistically, a radiation-responsive p53-TET2 axis decreases m5C on chromatin-associated RNAs (caRNAs), enforcing immunosuppressive chromatin compaction and silencing interferon signaling, whereas Tet2 loss restores chromatin accessibility and enhances CD8+ T cell cytotoxicity. Pharmacological TET2 inhibition recapitulates this phenotype and augments radiotherapy and PD-L1 blockade to control primary and metastatic tumors. These findings define MDACs as an immunogenic myeloid subset and establish myeloid reprogramming as a strategy to improve radiotherapy-immunotherapy outcomes.
-
Priming of CD8+ T cells by peripheral dendritic cells exacerbates tau-mediated neurodegeneration.
In Nat Neurosci on 3 September 2026 by Hu, H., Lin, P. B., et al.
PubMed
Alzheimer's disease and primary tauopathies are marked by changes in adaptive immunity, with increased brain CD8+ T cells correlating with tau pathology severity. However, how peripheral T cells get primed to enter the brain and contribute to tau-mediated neurodegeneration remains unclear. In different disease conditions, conventional type 1 dendritic cells (cDC1s) cross-present antigens to prime CD8+ T cells into effector cells. We show that tauopathy mice lacking cDC1s or antigen cross-presentation are protected from neurodegeneration, with reduced brain CD8+ T cell infiltration and glial activation. The remaining CD8+ T cells exhibit limited clonal expansion, consistent with impaired priming. We further demonstrate that brain-derived antigens are presented in secondary lymphoid tissues, suggesting a site of T cell activation. Together, these findings establish cDC1-dependent peripheral priming as a key driver of CD8+ T cell accumulation in the brain and tau-mediated neurodegeneration.
-
Priming of CD8+ T cells by peripheral dendritic cells exacerbates tau-mediated neurodegeneration.
In Nat Neurosci on 3 September 2026 by Hu, H., Lin, P. B., et al.
PubMed
Alzheimer's disease and primary tauopathies are marked by changes in adaptive immunity, with increased brain CD8+ T cells correlating with tau pathology severity. However, how peripheral T cells get primed to enter the brain and contribute to tau-mediated neurodegeneration remains unclear. In different disease conditions, conventional type 1 dendritic cells (cDC1s) cross-present antigens to prime CD8+ T cells into effector cells. We show that tauopathy mice lacking cDC1s or antigen cross-presentation are protected from neurodegeneration, with reduced brain CD8+ T cell infiltration and glial activation. The remaining CD8+ T cells exhibit limited clonal expansion, consistent with impaired priming. We further demonstrate that brain-derived antigens are presented in secondary lymphoid tissues, suggesting a site of T cell activation. Together, these findings establish cDC1-dependent peripheral priming as a key driver of CD8+ T cell accumulation in the brain and tau-mediated neurodegeneration.
-
Optimising Recovery of Hepatic Regulatory T Cells: A Practical Guide Using ARTC2 Blockade.
In Eur J Immunol on 1 December 2025 by Abbott, C. A., Mouro, V., et al.
PubMed
This is an update to the Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition), Chapter 3: 12C, by Cossarizza et al. Administration of anti-ARTC2 nanobody(S+16a) prevents cell death during tissue processing. We demonstrate that the phenotype of CD44midTreg is significantly impacted, whereas the eTreg phenotype remains stable following S+16a treatment, outlining specific protocols for population recovery.